• Profile
Close

Effect of group-administered behavioral treatment on urinary incontinence in older women: A randomized clinical trial

JAMA Internal Medicine Sep 09, 2018

Diokno AC, et al. - This multisite, randomized clinical trial (the Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms [GLADIOLUS] study) compared the effectiveness, cost, and cost-effectiveness of group-administered behavioral treatment (GBT) with no treatment for urinary incontinence (UI) in older women. Results showed that a one-time GBT program is modestly effective and cost-effective for decreasing UI frequency, severity, and bother, and improving patient quality of life. For older women with UI, GBT is a promising first-line approach to enhancing access to noninvasive behavioral treatment.

Methods

  • This study was conducted from July 7, 2014, to December 31, 2016.
  • Outpatient practices at three academic medical centers comprised the setting.
  • Study participants were community-dwelling women aged ≥55 years with UI, and were enrolled via mail and screened for eligibility, which included a score of ≥3 on the International Consultation on Incontinence Questionnaire–Short Form (ICIQ-SF), symptoms of ≥3 months’ duration, and absence of medical conditions or treatments that could affect continence status.
  • A total of 1125 of 2171 mail respondents were invited for clinical screening; 463 were eligible and randomized, and 398 completed the 12-month study.
  • For this analysis, the GBT group received a one-time 2-hour bladder health class, supported by written materials and an audio CD.
  • Researchers measured outcomes at in-person visits (at 3 and 12 months) and by mail or telephone (at 6 and 9 months).
  • Change in ICIQ-SF score was the primary outcome.
  • Secondary outcome measures included UI severity, quality of life, perceptions of improvement, pelvic floor muscle strength, and costs.
  • Evaluators were masked to group assignment.

Results

  • Study participants (GBT group, n=232; control group, n=231) were aged 55 to 91 years (mean [standard deviation] age: 64 [7] years), and 46.2% (214/463) were African American.
  • The ICIQ-SF scores for the GBT group were consistently lower versus the control group across all time points but did not achieve the projected three-point difference in intent-to-treat analyses.
  • The difference in differences at 3 months was 0.96 points (95% confidence interval: -1.51 to -0.41), which was statistically significant but clinically modest.
  • Findings revealed that the mean (standard error) treatment effects at 6, 9, and 12 months were 1.36 (0.32), 2.13 (0.33), and 1.77 (0.31), respectively.
  • Apart from pelvic floor muscle strength, significant group differences were observed at all time points in favor of GBT on all secondary outcomes.
  • The incremental cost to achieve a treatment success was $723 at 3 months; GBT dominated at 12 months.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay